EE200200149A - Kinasoliinühendid ja neid sisaldavad ravimkoostised - Google Patents

Kinasoliinühendid ja neid sisaldavad ravimkoostised

Info

Publication number
EE200200149A
EE200200149A EEP200200149A EEP200200149A EE200200149A EE 200200149 A EE200200149 A EE 200200149A EE P200200149 A EEP200200149 A EE P200200149A EE P200200149 A EEP200200149 A EE P200200149A EE 200200149 A EE200200149 A EE 200200149A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
compositions containing
quinazoline compounds
quinazoline
compounds
Prior art date
Application number
EEP200200149A
Other languages
English (en)
Inventor
Austen Mortlock Andrew
John Keen Nicholas
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9922159.0A external-priority patent/GB9922159D0/en
Priority claimed from GBGB9922152.5A external-priority patent/GB9922152D0/en
Priority claimed from GBGB9922156.6A external-priority patent/GB9922156D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200200149A publication Critical patent/EE200200149A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials
EEP200200149A 1999-09-21 2000-09-18 Kinasoliinühendid ja neid sisaldavad ravimkoostised EE200200149A (et)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9922159.0A GB9922159D0 (en) 1999-09-21 1999-09-21 Chemical compounds
GBGB9922152.5A GB9922152D0 (en) 1999-09-21 1999-09-21 Chemical compounds
GBGB9922156.6A GB9922156D0 (en) 1999-09-21 1999-09-21 Chemical compounds
PCT/GB2000/003556 WO2001021594A1 (en) 1999-09-21 2000-09-18 Quinazoline compounds and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
EE200200149A true EE200200149A (et) 2003-04-15

Family

ID=27269803

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200149A EE200200149A (et) 1999-09-21 2000-09-18 Kinasoliinühendid ja neid sisaldavad ravimkoostised

Country Status (20)

Country Link
US (1) US7081461B1 (et)
EP (1) EP1218356A1 (et)
JP (1) JP2003509497A (et)
KR (1) KR20020032608A (et)
CN (1) CN1391561A (et)
AU (1) AU763242B2 (et)
BG (1) BG106491A (et)
BR (1) BR0014133A (et)
CA (1) CA2384282A1 (et)
CZ (1) CZ20021010A3 (et)
EE (1) EE200200149A (et)
HK (1) HK1046688A1 (et)
HU (1) HUP0204413A3 (et)
IL (1) IL148489A0 (et)
IS (1) IS6304A (et)
NO (1) NO20021401L (et)
PL (1) PL354923A1 (et)
SK (1) SK3832002A3 (et)
TR (1) TR200200749T2 (et)
WO (1) WO2001021594A1 (et)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135466B2 (en) 1999-12-24 2006-11-14 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives and drugs containing the same
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
PL202812B1 (pl) 2000-08-21 2009-07-31 Astrazeneca Ab Pochodna chinazoliny, jej kompozycja famaceutyczna oraz jej zastosowanie
US6939866B2 (en) 2000-10-13 2005-09-06 Astrazeneca Ab Quinazoline derivatives
JP2004511479A (ja) 2000-10-13 2004-04-15 アストラゼネカ　アクチボラグ キナゾリン誘導体
WO2002036587A2 (en) 2000-11-01 2002-05-10 Cor Therapeutics, Inc. Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
US7141577B2 (en) 2001-04-19 2006-11-28 Astrazeneca Ab Quinazoline derivatives
EP1408980A4 (en) 2001-06-21 2004-10-20 Ariad Pharma Inc NEW QUINAZOLINES AND THEIR USE
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
KR101019131B1 (ko) * 2001-11-19 2011-03-07 인터레우킨 제네틱스, 인코포레이티드 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에영향을 미치는 인터루킨-1 좌의 기능적 다형성
RS63204A (en) 2002-01-17 2006-10-27 Neurogen Corporation Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
US6924285B2 (en) * 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2004004732A1 (en) * 2002-07-09 2004-01-15 Astrazeneca Ab Quinazoline derivatives for use in the treatment of cancer
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
US7560558B2 (en) 2002-08-23 2009-07-14 Kirin Beer Kabushiki Kaisha Compound having TGFβ inhibitory activity and medicinal composition containing the same
DK1562955T3 (da) 2002-11-04 2008-06-02 Astrazeneca Ab Quinazolinderivater som Src-tyrosinkinaseinhibitorer
US7488823B2 (en) * 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
EP1575966B1 (en) * 2002-12-24 2008-10-29 AstraZeneca AB Therapeutic quinazoline derivatives
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
CN102432552B (zh) 2003-08-14 2016-01-20 阿雷生物药品公司 作为受体酪氨酸激酶抑制剂的喹唑啉类似物
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
DE602004022318D1 (de) 2003-10-14 2009-09-10 Supergen Inc Proteinkinaseinhibitoren
WO2005042498A2 (en) * 2003-10-31 2005-05-12 Neurogen Corporation 4-amino (aza) quinoline derivatives as capsaicin receptor agonists
US20050197371A1 (en) * 2003-11-13 2005-09-08 Ambit Biosciences Corporation Urea derivatives as PDGFR modulators
BRPI0400869B8 (pt) * 2004-03-02 2021-05-25 Univ Estadual Campinas Unicamp novos compostos derivados de 4-anilinoquinazolinas com propriedade inibidora de adenosinacinases
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
AR050948A1 (es) 2004-09-24 2006-12-06 Hoffmann La Roche Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
BRPI0516093A (pt) 2004-10-12 2008-08-19 Astrazeneca Ab derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
WO2006044687A2 (en) 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
ES2450566T3 (es) 2004-11-30 2014-03-25 Amgen Inc. Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
PT1854789E (pt) 2005-02-23 2013-10-23 Shionogi & Co Derivado de quinazolina possuindo actividade inibidora de tirosina-cinase
JP2008535876A (ja) 2005-04-14 2008-09-04 エフ．ホフマン−ラ ロシュ アーゲー アミノピラゾール誘導体、これらの製造、及び医薬製剤としての使用。
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0509224D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of intracellular enzymatic activity
WO2007033196A1 (en) 2005-09-14 2007-03-22 Bristol-Myers Squibb Company Met kinase inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
ATE507224T1 (de) * 2005-11-15 2011-05-15 Array Biopharma Inc Verfahren und zwischenverbindungen zur herstellung von n4-phenyl-quinazolin-4-amin derivaten
CN101003514A (zh) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 喹唑啉衍生物、其制备方法及用途
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) * 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
WO2009030224A2 (de) * 2007-09-07 2009-03-12 Schebo Biotech Ag Neue chinazolin- verbindungen und ihre verwendung zur therapie von krebserkrankungen
WO2009058937A2 (en) * 2007-11-01 2009-05-07 Wyeth Heteroaryl ethers and processes for their preparation
CA2711582A1 (en) 2008-02-07 2009-08-13 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles, formulations containing said compounds, use thereof and processes for the preparation thereof
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
KR20160129109A (ko) 2008-05-23 2016-11-08 아미라 파마슈티칼스 인코포레이티드 5-리폭시게나아제 활성화 단백질 억제제
JP5539351B2 (ja) 2008-08-08 2014-07-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
CN101857588B (zh) * 2010-06-08 2013-11-27 东南大学 4-芳香胺基喹唑啉类衍生物及其用途
CN102850280B (zh) * 2011-06-30 2015-06-10 陕西师范大学 6,7-二烷氧基-4-取代苯基氨基喹唑啉类化合物及其制备方法
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
CA2981886A1 (en) 2015-04-16 2016-10-20 Icahn School Of Medicine At Mount Sinai Ksr antagonists
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
CN113354591B (zh) * 2021-06-09 2023-03-24 广东湛江海洋医药研究院 烷氨基喹唑啉的合成及其抗肿瘤活性

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2102780C (en) * 1991-05-10 2007-01-09 Alfred P. Spada Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (et) * 1994-11-12 1997-12-01 Zeneca Ltd
EP2163546B1 (en) 1995-03-30 2016-06-01 Pfizer Products Inc. Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6184225B1 (en) * 1996-02-13 2001-02-06 Zeneca Limited Quinazoline derivatives as VEGF inhibitors
GB9603095D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
DE69709319T2 (de) * 1996-03-05 2002-08-14 Astrazeneca Ab 4-anilinochinazolin derivate
MXPA00011773A (es) * 1998-05-28 2002-06-04 Parker Hughes Inst Quinazolinas para tratar tumores en el cerebro.

Also Published As

Publication number Publication date
CN1391561A (zh) 2003-01-15
PL354923A1 (en) 2004-03-22
BG106491A (bg) 2002-12-29
CZ20021010A3 (cs) 2002-06-12
SK3832002A3 (en) 2002-11-06
HUP0204413A3 (en) 2003-07-28
IL148489A0 (en) 2002-09-12
NO20021401L (no) 2002-05-21
HUP0204413A2 (en) 2003-05-28
US7081461B1 (en) 2006-07-25
EP1218356A1 (en) 2002-07-03
AU763242B2 (en) 2003-07-17
IS6304A (is) 2002-03-18
WO2001021594A1 (en) 2001-03-29
TR200200749T2 (tr) 2002-06-21
CA2384282A1 (en) 2001-03-29
HK1046688A1 (zh) 2003-01-24
BR0014133A (pt) 2002-06-11
KR20020032608A (ko) 2002-05-03
AU7432500A (en) 2001-04-24
NO20021401D0 (no) 2002-03-20
JP2003509497A (ja) 2003-03-11

Similar Documents

Publication Publication Date Title
EE200200149A (et) Kinasoliinühendid ja neid sisaldavad ravimkoostised
EE200000168A (et) Karboksamidotiasoolderivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
ATE246490T1 (de) Pharmazeutische zusammensetzung von topiramate
EE200200138A (et) Kinolüülpropüülpiperidiini derivaadid, nende valmistamine ja neid sisaldavad kompositsioonid
EE05034B1 (et) Bitsüklilised heterotsüklilised ühendid, neid ühendeid sisaldavad farmatseutilised kompositsioonid ja nende valmistamise meetodid
EE04799B1 (et) Ühendid, mis on kasulikud põletikuvastaste vahenditena, nende ühendite valmistamise meetodid ja neid sisaldavad farmatseutilised kompositsioonid
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
HUP0203939A3 (en) Pharmaceutical compounds and compositions containing them and their use
FI991485A0 (fi) Uusi farmaseuttinen koostumus
EE04673B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
NO20015175D0 (no) Farmasöytisk sammensetning
HUP0203378A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
ATE401908T1 (de) Pharmazeutische zusammensetzungen von erythropoietin
EE04276B1 (et) Kinoliini derivaadid, nende valmistamine ja kasutamine ravimina ning neid sisaldavad farmatseutilised kompositsioonid
DE69900561D1 (de) Pharmazeutische Zusammensetzungen enthaltend Mupirocin
ITMI982222A0 (it) Composizioni farmaceutiche orali contenenti buprenorfina
DE60037816D1 (de) Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka
ID27201A (id) Komposisi farmasi
EE200200342A (et) Asendatud 8-arüülkinoliinid, nende kasutamine, farmatseutiline kompositsioon ja prekursorühend
HUP0200747A3 (en) Pharmaceutical compounds and pharmaceutical compositions containing them
EE200200022A (et) Aminotiasooli derivaadid, nende valmistamine ja neid sisaldavad farmatseutilised kompositsioonid
HUP0200468A3 (en) Resorcinol derivatives and pharmaceutical compositions containing them
EE05192B1 (et) Trptamiini derivaadid ja analoogsed hendid ning neid sisaldavad farmatseutilised preparaadid
PT1227817E (pt) Composicao farmaceutica aquosa contendo ciclesonida